v3.26.3
Supplemental Financial Information - Schedule of Foreign Exchange and Other Income/(Expense) (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]            
Gain on sale of investment   $ 0 $ 0 $ 13,648 $ 0  
Interest income   3,896 3,899 11,279 14,525  
FX fluctuations   (1,039) (613) (2,407) (2,463)  
Impairment of investment   0 (1,112) (1,132) (1,112)  
Investment revaluation - Ceribell, Inc.   0 0 0 (3,622)  
Other   (8) 400 195 527  
Foreign exchange and other income/(expense)   26,301 $ (7,493) (3,223) (332)  
Consideration receivable       7,991 $ 0  
Equity Investment Acquired By Third Party            
Derivative Instruments, Gain (Loss) [Line Items]            
Consideration receivable $ 17,100          
Ceribell, Inc.            
Derivative Instruments, Gain (Loss) [Line Items]            
Number of shares issued in transactions (in shares)         391,952  
Average sales price (in dollars per share)     $ 16.69   $ 16.69  
Net proceeds         $ 6,500  
Equity method investment           $ 3,000
2029 Embedded Derivative | 2029 Notes            
Derivative Instruments, Gain (Loss) [Line Items]            
Fair value adjustment   28,152 $ (16,422) (40,848) (12,696)  
2029 Embedded Derivative | 2025 Notes            
Derivative Instruments, Gain (Loss) [Line Items]            
Fair value adjustment   0 (322) 0 1,230  
2029 Capped Calls | 2029 Notes            
Derivative Instruments, Gain (Loss) [Line Items]            
Fair value adjustment   (4,700) 6,353 16,042 4,276  
2029 Capped Calls | 2025 Notes            
Derivative Instruments, Gain (Loss) [Line Items]            
Fair value adjustment   $ 0 $ 324 $ 0 $ (997)